EN DE
Watch Teleflex Incorporated for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Teleflex Incorporated (TFX) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Teleflex Incorporated stock $47.58, price $151, that is 68.5% below the price, quality 52 out of 100. Rating: strongly overvalued. Calculated from audited financials with 12 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

TI Teleflex Incorporated logo Some data Nov 7, 2026

Teleflex Incorporated

TFX · US
Solid, but very expensive

Our calculation puts a fair price 68% below what the stock costs today.

Generates free cash flow
0.9% dividend yield · Sustainable
Upbeat coverage
Revenue last quarter +29% vs. a year ago.
Quality 52/100
Mixed Growth (revenue 5y +3.3 %/yr in USD)
Moderate debt
Some data
Fair value $47.58 · Strongly overvalued (−68.5%)
Loss-making · -45.8% net margin (TTM)
Trails peers (2/13)
Narrow moat 25/100 · thin data

Risks from the AI analysis

🚩Rivals like Medtronic could pressure prices🚩Patent litigation with Medtronic on catheters🚩FDA and international regulatory hurdles
Watch Teleflex Incorporated for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$389.69 $99.54 Fair Value $47.58 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.

How to read this chart

60‑month range $99.54 – $389.69 · fair‑value band $32.98 – $73.24 · the $150.87 price screens above the $47.58 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 7, 2026.

Follow Teleflex in your weekly email

Every Wednesday you see whether Teleflex is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications in the United States, Europe, the Middle East, Africa, the Asia Pacific, and internationally.

Show moreShow less

The company offers vascular and emergency medicine products comprising Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous bone access systems for the administration of intravenous therapies, measurement of blood pressure, and collection of blood samples; intraosseous access systems consisting of EZ-IO intraosseous vascular access systems, and Arrow FAST1 sternal intraosseous infusion systems; and hemostatic products, including external hemostats and trauma products under the QuikClot brand.

It also provides interventional products, including various coronary catheters, structural heart support devices, and peripheral intervention products platforms; GuideLiner, Turnpike, and TrapLiner catheters; MANTA vascular closure devices and Arrow OnControl powered bone biopsy systems; and coronary and peripheral medical devices, such as drug-coated balloons, stents, and balloon catheters.

In addition, the company offers surgical products, including metal and polymer ligating clips using manual and automatic applier system, fascial closure surgical systems used in laparoscopic surgical procedures, percutaneous surgical systems, powered bariatric staplers, and other surgical instruments under the Weck, MiniLap, Pleur-Evac, Deknatel, KMedic, Pilling, and Titan SGS brands.

It serves hospitals, healthcare providers, and medical device manufacturers. The company also sells its products online. Teleflex Incorporated was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.

Stock analysis

Teleflex Incorporated (TFX) currently trades at $150.87, while our model-based Fair Value estimate is $47.58, 68% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of $64.81 per share, and 0 of the 12 models we run sit above the $150.87 price.

Bear case: the Earnings-Based group reads lowest at $7.61, and 12 of the 12 models stay below the price. Data coverage for this calculation is medium.

Scenario range: $32.98 (bear) to $73.24 (bull), the price of $150.87 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 52/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Teleflex Incorporated reported revenue of $2.0B in FY2025 versus $2.8B in FY2021, a compound −8.2%/yr. Reported net income was −$906M in FY2025.

Key figures

Market cap $6.6B Mid · P/S ratio 2.84 · EPS (TTM) $2.03 · Dividend yield 0.9% · Net margin −45.4% · Return on equity −0.7% · Return on assets (EBIT) 5.8% (5-year average) · Operating margin 10.1%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 25 out of 100 (low confidence).

What moves the price

The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat.

The share trades about 1% below its 52-week high and 52% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −45% fair-value upside, at −68%, TFX screens richer than that median.

Fair Value models

Bear $32.98 Fair Value $47.58 Bull $73.24
Price $150.87 · Downside -68.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($0.5727 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF $30.74 $64.81 $111.84 77
Growth DCF $32.98 $64.62 $106.46 76
5Y EBITDA Exit $38.55 $86.60 $139.98 72
All 12 models by family
DCF Models
FCF DCF $30.74 $64.81 $111.84 77
5Y Revenue Exit $11.92 $39.40 $72.69 68
5Y EBITDA Exit $38.55 $86.60 $139.98 72
10Y Revenue Exit $16.88 $42.46 $73.21 63
10Y EBITDA Exit $34.79 $73.85 $121.38 66
Earnings-Based
EPV n/a $7.61 $14.62 68
Multiples
EV/EBIT $21.93 $47.58 $73.24 62
EV/EBITDA $52.39 $88.20 $124.01 65
EV/Revenue n/a $23.44 $46.98 50
Growth DCF
Growth DCF $32.98 $64.62 $106.46 76
Rev-Margin DCF $11.92 $40.58 $71.45 68
Economic Profit
ROIC Compounder n/a $7.61 $14.62 68

Open the full fair value analysis →

Quality Score breakdown

Overall quality 52/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 8
How much profit the company makes from its sales and capital
Quality Growth 23
Are margins and returns getting better?
Cashflow 61
Do the profits arrive as real cash?
Financial strength 44
Debt, balance sheet and risk of trouble
Investment 95
Does it invest with discipline instead of growing at any price?
Low Volatility 62
How calm the share price moves, does not count
Price momentum 52
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 78
Distance to the 52-week high, does not count
New shares 100
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, no officer or director bought or sold shares on the open market.

Plus 10 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 6, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 42/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.3%
Revenue growth 39 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.7%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
16.7% (2020) → 12.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+19.4%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+5.8%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +16.6% a year for the price and +3.4% for the forecasts.
Forecast 2026 (sales)+13.8%
Forecast 2027 (sales)+4.3%
Projected 2028 (sales)+4.0%
Projected 2029 (sales)+3.8%
Projected 2030 (sales)+3.5%

TFX screens overvalued: fair value 68% below the price. Compare with Intuitive Surgical, Inc →

Earlier news

News mood ⓘNews mood, the average tone of recent news (99 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Hype
Recent news coverage is unusually upbeat, far more positive than stocks are typically covered.
Note from the team Oct 11, 2026
AI conclusion: Clinical strengths in vascular and surgical products such as Arrowg+ard technology form the main strength, while weak profitability with significant net losses and negative returns remain the main weak point.
Main risk: Larger rivals such as Medtronic, Boston Scientific and Becton Dickinson could intensify competition in vascular access and interventional segments, potentially squeezing prices and margins on core catheter and device offerings.
Bull case: Teleflex could leverage its resorbable magnesium scaffold technology and clinical data advantages to differentiate products and gain share despite rival pressure.
Bear case: If competition and regulatory pressures intensify, Teleflex might face sustained margin compression and slower adoption of its interventional portfolio in key hospital segments.
Teleflex has streamlined around vascular and surgical products after completing its OEM divestiture. A peer-reviewed study shows its Arrowg+ard technology cuts central line infection risk by 70 percent in critically ill patients. Integration delays in the interventional segment have lowered revenue growth expectations even while adjusted earnings guidance rose. Will clinical strengths in the core portfolio overcome these execution hurdles?
Join the discussion →

Compare Teleflex Incorporated with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 181 stocks

Beats the industry median on 2/12 measures
Overall it trails its industry peers.
Valuation
Quality Score 52 · Below median
Fair Value upside −68.5% · Bottom 25%
Profitability
Return on assets −13.0% · Bottom 25%
Net margin (12 months) −45.8% · Bottom 25%
Operating margin (12 months) 10.1% · Below median
Growth and dividend
Revenue growth (quarter YoY) 28.9% · Top 25%
Dividend yield (12 months) 0.9% · Below median
Balance sheet
Debt / equity 0.81× · Highest 25%

Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper

P/B 2.11× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (12 months) 2.92× · Pricier than median
Price / free cash flow (fiscal year) 26.8× · Pricier than median
EV/EBITDA 21.6× · Pricier than median
PEG 0.16× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 25
FUTURE (revenue growth)100 · sector 40
PAST (return on equity)0 · sector 31
HEALTH (low debt)59 · sector 96
DIVIDEND (yield)18 · sector 32

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Solventum Corporation SOLV $90.38 $131.06 +45% vs TFX
EssilorLuxottica Société anonyme EL €193.80 €196.22 +1% vs TFX
Intuitive Surgical, Inc ISRG $452.80 $353.90 −22% vs TFX
Medline Inc MDLN $39.64 $28.59 −28% vs TFX
Alcon Inc ALC CHF 61.30 CHF 33.91 −45% vs TFX
Straumann Holding STMN CHF 104.50 CHF 45.50 −56% vs TFX
Becton, Dickinson and Company BDX $211.88 $82.34 −61% vs TFX
West Pharmaceutical Services, Inc WST $399.81 $139.22 −65% vs TFX
Sartorius Stedim Biotech S.A DIM €225.80 €54.82 −76% vs TFX
Sartorius Aktiengesellschaft SRT €227.00 €42.50 −81% vs TFX

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Evidence & backtest34 years, failed companies included Financial calculatorsDCF, Graham, PEG and more
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Teleflex Incorporated: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Teleflex Incorporated Fair Value". https://www.fairvalue-calculator.com/stock/TFX

Frequently asked questions

Is Teleflex Incorporated (TFX) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of $47.58 versus a price of $150.87, about 68% lower (overvalued).
What is the fair value of TFX?
Our model-based fair value for Teleflex Incorporated is $47.58 (as of Nov 7, 2026), built from audited fundamentals. The current price: $150.87.
What is the quality score of TFX?
Teleflex Incorporated has a Quality Score of 52/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Teleflex Incorporated (TFX)?
Our model-based price target is the fair value of $47.58 (as of Nov 7, 2026) from 12 valuation models. Cautious scenario $32.98, optimistic scenario $73.24. It is a calculation from audited fundamentals, not an analyst target.
What is the Teleflex Incorporated stock forecast for 2026?
Our models put fair value at $47.58, about 68% lower versus a price of $150.87 (overvalued). Cautious scenario $32.98, optimistic scenario $73.24. The calculation is refreshed regularly with new filings.
What is the revenue of Teleflex Incorporated (TFX)?
Teleflex Incorporated reported trailing-twelve-month revenue of about $2.3B (latest available figure, as of Nov 7, 2026).
Does Teleflex Incorporated pay a dividend?
Teleflex Incorporated currently shows a dividend yield of 0.90% relative to its recent price (as of Nov 7, 2026).
How much is the dividend of Teleflex Incorporated (TFX) and when is the ex-dividend date?
Teleflex Incorporated pays a dividend of $1.36 per share a year, a dividend yield of 0.9%. The last ex-dividend date was Aug 14, 2026. A dividend has been paid every year since at least 1985. The payout ratio is 67.0% of earnings. Free cash flow covers the dividend 4.26 times. Our assessment: Sustainable. Payout and cash coverage both look sustainable.
What growth is priced into Teleflex Incorporated (TFX)?
For today's price to be fair in a discounted-cash-flow model, Teleflex Incorporated would have to grow free cash flow by +19.4 % per year for five years (discount rate 9.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -4.7 % per year. As of Nov 7, 2026.
What discount rate (WACC) does the fair value of TFX use?
Our models discount Teleflex Incorporated at 9.3 %: a base by market capitalisation (mid), damped by beta 0.83, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Teleflex Incorporated that is +19.4 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (9.3 %) and the same formula as our fair value.
How much growth has Teleflex Incorporated (TFX) delivered so far?
Over the past 5 years revenue at Teleflex Incorporated grew -4.7 % a year. The price currently implies free-cash-flow growth of +19.4 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Teleflex Incorporated (TFX) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Teleflex Incorporated (+19.4 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Teleflex Incorporated (TFX)?
The free-cash-flow yield on the price is 3.73 %: that much free cash flow Teleflex Incorporated produces per unit of market value. When it exceeds the discount rate of our models (9.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Teleflex Incorporated (TFX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Teleflex Incorporated it is $47.58 per share (as of Nov 7, 2026), against a price of $150.87. It is the blended result of 12 valuation models in 5 families (DCF Models, Earnings-Based, Multiples, Growth DCF, Economic Profit).
Is Teleflex Incorporated stock overvalued or undervalued in 2026?
As of Nov 7, 2026, TFX trades above its calculated fair value: price $150.87, fair value $47.58, a gap of about −68% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of TFX?
No. The price is what the market pays today ($150.87); the fair value is what the company's own numbers justify ($47.58). For Teleflex Incorporated the two are $103.29 per share apart. That gap is exactly why we show both numbers side by side.
How much is Teleflex Incorporated worth?
The market values Teleflex Incorporated at about $6.6B (market capitalisation, as of Nov 7, 2026). Per share that is $150.87; our models calculate a fair value of $47.58 per share.
What do the bullish and bearish scenarios say about TFX?
Our models span a range for Teleflex Incorporated: cautious scenario $32.98, base $47.58, optimistic $73.24 per share (as of Nov 7, 2026, price $150.87). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of TFX?
The PEG ratio of Teleflex Incorporated is 0.16 (P/E divided by earnings growth, as of Nov 7, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of Teleflex Incorporated (TFX)?
Balance-sheet figures for Teleflex Incorporated (as of Nov 7, 2026): return on equity −0.7%, debt of 0.81 per unit of equity. They feed the Quality Score of 52/100, which measures business quality independently of the share price.
How far is TFX from its 52-week high?
Teleflex Incorporated trades at $150.87, about 1% below its 52-week high of $152.15 and 52% above the low of $99.54 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $47.58 is for.
Which stocks are comparable to Teleflex Incorporated?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Teleflex Incorporated stock attractive at the current price?
The data as of Nov 7, 2026: price $150.87, calculated fair value $47.58 (−68%), Quality Score 52/100, from 12 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of TFX calculated?
We run Teleflex Incorporated through 12 models from 5 families: DCF Models, Earnings-Based, Multiples, Growth DCF, Economic Profit. Every model gets the same audited fundamentals; the fair value of $47.58 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Teleflex Incorporated itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Teleflex Incorporated (TFX)?
The closing price on Nov 6, 2026 was $150.87. Our model-based fair value is $47.58, about 68% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Teleflex Incorporated right now?
The price sits above even our optimistic bull case ($73.24). The favourable scenario is already priced in. Solid but not exceptional quality (52/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range ($32.98 to $73.24) leaves room in how you read the outcome.
Where does the earnings growth of Teleflex Incorporated (TFX) come from?
Earnings per share at Teleflex Incorporated grew −0.5 % a year from 2014 to 2025. Broken into its drivers: revenue per share +6.0 %, EBIT margin −4.9 %, tax rate −1.3 %, residual (interest, one-offs) −0.1 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Teleflex Incorporated

How large is the market capitalisation of Teleflex Incorporated (TFX)?
The market capitalisation of Teleflex Incorporated is $6.6B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Teleflex Incorporated (TFX)?
The price-to-sales ratio of Teleflex Incorporated is 2.84 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Teleflex Incorporated (TFX)?
Earnings per share at Teleflex Incorporated are $2.03. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Teleflex Incorporated (TFX)?
The dividend yield of Teleflex Incorporated is 0.9% (payout 67.0%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Teleflex Incorporated (TFX)?
The net margin of Teleflex Incorporated is −45.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Teleflex Incorporated (TFX)?
The return on equity (ROE) of Teleflex Incorporated is −0.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Teleflex Incorporated (TFX)?
On an EBIT basis the return on assets of Teleflex Incorporated is 5.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Teleflex Incorporated (TFX)?
The operating margin of Teleflex Incorporated is 10.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Teleflex Incorporated (TFX)?
Revenue at Teleflex Incorporated is growing +28.9% versus a year earlier (3y avg −10.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Teleflex Incorporated (TFX)?
Earnings per share at Teleflex Incorporated are growing −17.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Teleflex Incorporated (TFX) carry?
The net debt of Teleflex Incorporated is $2.3B (fiscal year 2025, ≈ 9.5 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Teleflex Incorporated in the live analysis

One click puts Teleflex Incorporated on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.